Physician profile
Zhuowei Wang
NPI 1942240056
$900.87
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $520 · 2020: $116 · 2021: $32.44 · 2022: $183 · 2023: $50.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $47.29 · Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $47.29 |
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $142.57 | 2019-2020 | |
| Medtronic, INC. | $126.93 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $115.40 | 2019-2021 | |
| Akebia Therapeutics INC | $113.23 | 2019-2020 | |
| Nevro Corp. | $102.96 | 2019 | |
| Horizon Therapeutics Plc | $72.25 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $47.29 | 2023 | Empaveli |
| Allergan, INC. | $39.42 | 2019-2020 | |
| Fresenius USA Marketing, INC. | $37.58 | 2019 | |
| Amgen INC. | $32.95 | 2020 | |
| Mallinckrodt Enterprises LLC | $29.23 | 2019 | |
| Ferring Pharmaceuticals INC. | $19.28 | 2022 | |
| Vifor Pharma, INC. | $18.70 | 2019 | |
| Travere Therapeutics, INC. | $3.08 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zhuowei Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.